PATIENT ALERT:  The front entrance and adjacent parking lot at the Brock Cancer Center in Norfolk will be closed for construction from 4/17-5/2. Please use the side entrance (Kempsville) during this time. Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. Thank you. CLICK HERE for more details​​​​​​.

Clinical Research & Trials

USO 21536

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (GS-US-592-6173)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-Locally advanced (inoperable) or metastatic triple negative breast cancer that is PD-L1 positive with measurable disease
-Must have completed treatment for stage I-III as indicated with 6 ≥ months between finishing treatment with curative intent and documented disease recurrence, de novo metastatic triple negative breast cancer allowed
-No: previous treatment for advanced disease; prior therapy with agent directed to another stimulatory or coinhibitory T Cell receptor (CTLA-4, OX-40, CD137);
received systemic anticancer treatment within past 6 months or radiation treatment within last 2 weeks; received topoisomerase 1 inhibitors or antibody drug conjugates
containing isomerase inhibitor; HIV positive patients with history of Kaposi’s sarcoma and/or multicentric Castleman’s disease; active Hep B or Hep C infection; autoimmune disease requiring 
systemic treatment within past 2 years; have known active central nervous system metastasis or carcinomatous meningitis; allogenic tissue or solid organ transplant; myocardial infarction or unstable angina pectoris within last 6 months, history of ventricular arrhythmia or high grade atrioventricular block or other cardiac arrhythmias requiring antiarrhythmic medication, New York Heart Association Grade III or IV heart failure or ejection fraction < 40%, history of QT interval prolongation; have active chronic inflammatory bowel disease (ulcerative colitis or Crohn’s) or GI perforation in last 6 months; history of or active non-infectious pneumonitis or interstitial lung disease, history of active tuberculosis. 

Available at: